Le Lézard
Classified in: Health
Subject: ACC

Invitation to presentation of Q1 report

STOCKHOLM, April 27, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that it will present the interim report for the first quarter 2022 on May 4, at 11:00 (CET), and that the Annual General Meeting in Oncopeptides AB (publ) will be held on Tuesday June 28, 2022, (changed from May 19, 2022).

Investors, financial analysts, and media are invited to participate in a webcast including a QnA session on May 4. The event will be hosted by CEO, Jakob Lindberg and members of Oncopeptides' Leadership team, and the presentation will be held in English.

The webcast will be streamed via https://tv.streamfabriken.com/oncopeptides-q1-2022, and can also be found on the website: www.oncopeptides.com.

Dial in numbers for participants from:

For further information, please contact:                                       

Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB (publ) 
E-post: rolf.gulliksen@oncopeptides.com 
Mobil: + 46 70?262 96 28

About Oncopeptides

Oncopeptides is a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases. The company uses its proprietary PDC platform to develop peptide-drug conjugated compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from the PDC platform, Pepaxto® (INN melphalan flufenamide), also called melflufen was granted accelerated approval in the U.S., on February 26, 2021, in combination with dexamethasone, for treatment of adult patients with relapsed or refractory multiple myeloma. The Company voluntarily withdrew the drug on October 22, 2021, and thereafter rescinded the withdrawal on January 21, 2022. The product is currently not marketed in the U.S. Oncopeptides is developing several new compounds based on the PDC platform. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

This information was brought to you by Cision http://news.cision.com


The following files are available for download:


Invitation to presentation of Q1 report - webcast 20220404

SOURCE Oncopeptides AB

These press releases may also interest you

13 aoû 2022
At least 5% of Americans suffer from chronic low back pain. [1] Over $630 billion is spent annually on costs to society [2], and chiropractic care is essential in managed post-surgical spinal pain [3] and scoliosis [4]. To prepare clinicians...

13 aoû 2022
Ziegler is pleased to announce the successful closing of Shenandoah Valley Westminster-Canterbury's $71,000,000 Series 2022A and 2022B Bonds for the Senior Living Finance Practice. Shenandoah Valley Westminster-Canterbury (SVWC) is a Virginia...

12 aoû 2022
The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of LifeStance Health Group, Inc. common stock issued in connection with LifeStance Health's June 10, 2021 initial...

12 aoû 2022
An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen. Specifically, Daiichi Sankyo retains all patent rights to its antibody drug conjugate (ADC) technology and...

12 aoû 2022
Core One Labs Inc. , , (the "Company" or "Core One") is pleased to announce that scientists at its wholly-owned subsidiary Awakened Biosciences Inc. ("Awakened") have successfully produced a precursor that can be...

12 aoû 2022
Following the passage of the Inflation Reduction Act, Peter L. Saltonstall, President and CEO, the National Organization for Rare Disorders (NORD), issued the following statement:...

News published on 27 april 2022 at 09:27 and distributed by: